Hematide

AFFY (Common Stock)

Exchange Nasdaq CM
Price 6.03
Change(%) 0.836%
Volume 545,400

Data as of 09/02/10 4:00 PM ET Minimum 20 minute delay

Refresh Quote

Investor Overview

Corporate Profile

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax’s product candidate, Hematide™/peginesatide, has been investigated in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure.

Webcasts


Recent Press Releases



Transfer Agent

Computershare Trust Company, Inc.
350 Indiana Street, Suite 800, Golden, Colorado 80401
(800) 962-4284